Elotuzumab is a humanized IgG-1 monoclonal antibody targeting SLAMF7 that promotes NK-mediated ADCC, directly activates NK cells and interferes with the MM cell adhesion to the bone marrow stromal cells [63,64,65]. The gene discussed is SLAMF7; the disease is Miyoshi myopathy.